Emerging Markets Earnings Roundup: Sanofi And GSK (Part 6)

Emerging markets represent the biggest portion of Sanofi’s business, while GSK’s 10% growth in emerging markets for 2012 barely covered dismal European sales.

In a recurring feature, PharmAsia News combs through quarterly earnings reports to bring you highlights on emerging markets.

In Part 1, PharmAsia News looked at the emerging markets strategies of Amgen Inc. and Bristol-Myers Squibb Co....

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from China

More from Focus On Asia